The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | The use of bispecifics and CAR T-cells in South America: challenges that remain
In this video, Natalia Schütz, MD, Italian Hospital of Buenos Aires, Buenos Aires, Argentina, discusses the challenges of treating patients with multiple myeloma with bispecific antibodies and CAR T-cells in South America. Dr Schütz emphasizes issues such as infrastructure, team-building, and cost, as well as the inequities in accessing these innovative treatments. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
